Halozyme Therapeutics Inc. (HALO)
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
HALO Helps, But Dividend Investors Still Need to Be Selective
The latest buzz acronym in the investment community, spurred in part by the artificial intelligence (AI) trade, is HALO, or “heavy assets, low obsolescence.” The catchy acronym is relevant to dividend investors because many of the companies in the hard assets realm are dividend payers.
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO
Aquatic Capital Management LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 89,651 shares of the biopharmaceutical company's stock, valued at approximately $6,575,000. Aquatic Capital Management LLC owned about 0.08% of Halozyme Therapeutics as
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Hold” by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) has earned an average rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating on the company.
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Can AST SpaceMobile's HALO Contract Strengthen Its Defense Footprint?
ASTS lands a $30 million Space Development Agency contract to deploy BlueBird LEO satellites, advancing direct-to-device defense communications.
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge
Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 billion, with royalty revenue up 52%; recent acquisitions extend IP life and diversify the technology portfolio. 2026 guidance targets $1.71–$1.81 billion in revenue, over 70% EBITDA growth, and nearly 100% EPS growth, highlighting operating leverage and platform scalability.
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
